
Topical and intraurethral alprostadil significantly improve erectile dysfunction symptoms compared to placebo. A meta-analysis of 11 RCTs and 4 non-randomized studies (5869 patients) revealed a 4.7-point improvement in IIEF score with topical alprostadil and a significant odds ratio of 0.08 for intraurethral treatment. Despite small study numbers and variable designs, alprostadil is safe, with common mild side effects like penile pain and erythema.
Like
Save
Share